Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10164521 | 0.92 | ALDH1A1 (0.38) | LMNASMN1; SMN2ALDH1A1TRPA1KDM4E | |
| SCHEMBL10164625 | 0.91 | ALDH1A1 (0.36) | LMNAALDH1A1TRPA1MEN1KMT2A | |
| SCHEMBL10164564 | 0.89 | THRB (0.38) | LMNAMAPK1TRPA1MEN1KMT2A | |
| SCHEMBL10164576 | 0.88 | L3MBTL1 (0.45) | LMNASMN1; SMN2MAPK1ALDH1A1TRPA1 | |
| SCHEMBL10164566 | 0.87 | TRPA1 (0.41) | LMNAALDH1A1TRPA1MCHR1KDM4E | |
| SCHEMBL10164500 | 0.86 | VCP (0.39) | LMNAALDH1A1TRPA1MEN1KMT2A | |
| SCHEMBL893330 | 0.86 | TRPA1 (0.39) | LMNAALDH1A1TRPA1CHRM4 | |
| SCHEMBL894189 | 0.85 | HIF1A (0.40) | SMN1; SMN2TRPA1CHRM4KDM4EMAPT | |
| SCHEMBL10164606 | 0.85 | LMNA (0.40) | LMNASMN1; SMN2MAPK1ALDH1A1TRPA1 | |
| SCHEMBL894255 | 0.84 | TRPA1 (0.39) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | LMNA 4619/4885SMN1; SMN2 2836/4885MAPK1 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.